Physician profile
Thomas S Phillips
NPI 1053306431
$15,164.31
in general payments reported to CMS, 2019-2025
21 companies · $534 in 2025
The $534 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,316 · 2021: $294 · 2022: $502 · 2023: $521 · 2024: $461 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12,326.61 | 2019-2021 | |
| Alcon Vision LLC | $790.54 | 2019-2025 | Total30, Precision7 |
| Johnson & Johnson Vision Care, INC. | $442.33 | 2019-2024 | Acuvue |
| Bausch & Lomb Americas INC. | $431.25 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $317.58 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Onefit Contact Lens |
| Sun Pharmaceutical Industries INC. | $165.93 | 2019-2023 | Cequa |
| Oyster Point Pharma, INC. | $134.84 | 2022-2023 | Tyrvaya |
| Optovue, INC. | $118.47 | 2019 | |
| Harrow Eye, LLC | $71.33 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $55.81 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $44.71 | 2021 | |
| Glaukos Corporation | $36.52 | 2022 | |
| Visioneering Technologies, INC. | $36.41 | 2019-2020 | |
| Shire North American Group INC | $35.79 | 2019 | |
| Dompe US, INC. | $34.02 | 2025 | Oxervate |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $27.77 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $26.14 | 2023 | |
| Allergan, INC. | $18.14 | 2021 | |
| Astellas Pharma US INC | $18.14 | 2025 | Izervay |
| Abbvie INC. | $16.15 | 2022 | |
| Abb Con-Cise Optical Group LLC | $15.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.